Jill Abbey

Statistics

Publications

Citations

H-Index

Active since

2021

Affiliations

University of California, San Francisco(Current)

The Barbara Ann Karmanos Cancer Institute

UCSF Helen Diller Family Comprehensive Cancer Center

Phusis Therapeutics (United States)

Northwestern University

Jill Abbey is an author at University of California, San Francisco specializing in cancer pharmacology, medicine, and castration-resistant prostate cancer therapy.

Publications per year

2021–2025

Publications

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).

Rahul Aggarwal, Jacqueline Vuky, David James VanderWeele et al. · Journal of Clinical Oncology · 2022 · 23 citations

Medicine, Oncology, Pharmacology +17

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

Rahul Aggarwal, Jacqueline Vuky, David James VanderWeele et al. · Journal of Clinical Oncology · 2025 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17

P-225: A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma

Sandy W. Wong, Philip Imus, Tomer M. Mark et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 11 citations

Medicine, Hematology, Oncology +9

1–3 of 3